Experimental drug slows decline in lung function in pulmonary fibrosis patients

Bristol Myers Squibb announced positive results from a Phase 3 clinical trial of an experimental drug (admilparant) that showed slowing of lung function decline in patients with idiopathic pulmonary fibrosis. The trial included 1,255 patients over 52 weeks. The lower dose (60 mg) met the primary endpoint, while the higher dose (120 mg) did not. The drug remains experimental.

Bristol Myers Squibb announced positive results from a Phase 3 clinical trial of an experimental drug known as admilparant, which showed the ability to slow the decline in lung function in patients with idiopathic pulmonary fibrosis. The trial included 1,255 patients over 52 weeks. Results showed that the lower dose of 60 mg twice daily met the primary endpoint with statistical significance, while the higher dose of 120 mg did not. The study relied on measuring forced vital capacity of the lungs. The drug works by inhibiting the LPA1 protein receptor associated with fibrotic tissue formation. The drug remains experimental and has not received regulatory approvals. The company is conducting another Phase 3 trial in patients with progressive pulmonary fibrosis, with results expected in early 2027. Current treatments include nintedanib and pirfenidone.